Monday, July 24, 2000
With its planned acquisition of Anesta Corp. for $444 million in stock, Cephalon Inc. has put in place a major piece in its plan to become a profitable specialty pharmaceutical company. NSTA brings three key assets to the party: a marketed product, a drug delivery platform, and an oncology sales force.
Almost a year ago, CEPH (West Chester, Penn.) told BioCentury
that it planned to build the company's product pipeline and sales force in the
areas of neurology and oncology (see BioCentury, Aug.16, 1999). According
to CEO Frank Baldino, NSTA fits the program by complementing CEPH's existing
capabilities in neurological and oncological research, and leveraging its existing
sales force in neurology.